Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial.
Necchi A, Roumiguié M, Kamat AM, Shore ND, Boormans JL, Esen AA, Lebret T, Kandori S, Bajorin DF, Krieger LEM, Niglio SA, Uchio EM, Seo HK, de Wit R, Singer EA, Grivas P, Nishiyama H, Li H, Baranwal P, Van den Sigtenhorst-Fijlstra M, Kapadia E, Kulkarni GS.
Necchi A, et al. Among authors: seo hk.
Lancet Oncol. 2024 May 10:S1470-2045(24)00178-5. doi: 10.1016/S1470-2045(24)00178-5. Online ahead of print.
Lancet Oncol. 2024.
PMID: 38740030